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Practical Guidelines for DNA-Based Testing in Multiple Endocrine 
Neoplasia Type 1 
Catharina Larsson,* Magnus Nordenskjold,* Britt Skogseid,^  and Kjell Oberg* 
Multiple endocrine neoplasia type I (MEN I) is an autosomal dominant predisposition to neoplastic 
lesions ofthe parathyroid glands, the neuroendocrine pancreas, and the anterior pituitary gland. The 
predisposing genetic defect was localized to the long arm of chromosome 11 by genetic linkage 
analysis in three affected families. By analyzing six MEN I families with 14 DNA marker systems 
located close to the MEN I gene, we have developed a method to identify carriers of the MEN I 
predisposition. We describe practical aspects of such DNA-based diagnostic procedures. (Henry 
FordHospMedJ 1992;40:173-6] 
I t is generally believed that morbidity and mortality in neo-plastic diseases may be reduced by prevention, early detec-
tion, and by identifying individuals "at increased risk." In multi-
ple endocrine neoplasia type 1 (MEN 1) the two latter goals are 
approached by offering biochemical screening programs to the 
members of these families. Since the MEN 1 predisposition has 
a genetic origin, the utilization of such screening programs is 
largely dependent on factors such as mode of inheritance, pene-
trance, expression, and age of onset. The familial and genetic 
nature of the disease was first pointed out by Wermer (1) in 1954 
who suggested that an autosomal dominant gene with high pen-
etrance controlled the trait. The clinical picture is variable, de-
pending largely on the glands involved and whether or not the 
lesions hypersecrete symptom-causing hormones. The parathy-
roid glands are most frequentiy involved, followed by the neu-
roendocrine pancreas and the anterior pituitary gland. It has 
been shown that the age of diagnosis may be lowered by approx-
imately two decades by screening (2). On the other hand, the re-
ported ages of onset range from 6 to 81 years (3,4) which makes 
it difficuh to exclude family members from being at risk. Thus, 
children of unaffected family members at risk are sometimes 
also included in the screening programs. Furthermore, the much 
more common sporadic counterparts of MEN 1-associated neo-
plastic lesions may mimick the MEN 1 phenotype. Hence, the 
diagnosis of the MEN 1 predisposition would benefit from a 
method to detect carriers of the gene (MEN 1). 
Methods for DNA Testing 
Clinical cases 
The five Swedish families with MEN 1 have been described 
elsewhere (5,6). The sixth family is a large pedigree from Tas-
mania, first reported by Shepherd (7) in 1985 in which over 150 
affected individuals from 2,300 family members spanning eight 
generations had been traced back to a woman who came to Tas-
mania in the middle of the last century (8). The description of 
this patient recorded by the ship's surgeon is consistent with the 
diagnosis of MEN 1. 
The scoring for MEN 1 was conservative in order to avoid in-
correct diagnoses. Unaffected individuals at risk were scored as 
"normal" only if they had passed the age of 35 years and had un-
dergone repeated and extensive biochemical screenings (2) with 
no signs of the disease, while offspring of MEN 1 cases who did 
not fulfill these criteria were scored as "unknown." 
DNA probes and Southern analysis 
A set of DNA probes suitable for DNA testing is described 
in the Table. Dl lS288/pTHH26, Dl lS149/p3C7, PYGM/ 
pMCMPl, and DllS146/pHB159 are available from ATCC. 
CD20 was obtained from T. F. Tedder, pcAGP9/PGA from B. 
Zelle, DllS97/pMS51 from ICI, INT2/SS6 from N. Spurr, 
clone 8/Dl 1S751 from T. Rabbits, and the newly isolated cos-
mid clones for D11S480, D11S427, and D11S449 from Y. 
Nakamura. New allele systems were identified through locus 
expansion in cosmids for PGA (cCLPGA12), PYGM (cCL15), 
D11S146 (cCL59), and DllS751/clone 8 (cCL8). Two new 
cosmid clones, Dl lS750/cCLGW4 and Dl lS807/cCLGW39, 
were isolated from a library constructed from radiation-reduced 
somatic cell hybrids containing the 1 Iql2-ql3 region (9). 
Three marker systems (D11S146, Dl 1S751, and INT2) with 
two separate 2-allele restriction fragment length polymor-
phisms (RFLPs) can be combined to 4-allele systems by hap-
lotyping. The markers Dl 1S288 and Dl IS 149 can also be com-
bined by haplotyping to increase their relative information con-
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Table 
DNA Markers Linked to the MEN 1 Locus 
Locus Probe Constant Allele Allele Electi-ophoresis* 
Name Name Enzyme Bands Sizes(kb) Fi-equency (% agarose, length) 
D11S288 p3C7 Mspl 5.7 0,72 
D11S149 pTHH26 PvuII 3.1 
5.2 
3.2 
0,28 
0,14 
0.84 
CD20 pBl-2I Mspl 2.8 y.o 
A.O 
0,47 
0,53 
D1IS480 cCIlI-319® Pstl several 3.0 
1.4 
0.50 
0.50 
PGA pcAGP9 EcoRl 19.0 
16.6-I-15-H3.5 
I6,6-i-15-hI2-i-3.5 
0.06 
0.37 
0.54 0,5-0.6%, 30 cm 
CCLPGAI2® PvuII several 11 
6-H5 
0.37 
0.63 
PYGM pMCMPI® Mspl 2.2-2.5 5 alleles 1.1%, 30 cm 
cCL15® EcoRl 14; 6.6; 5.4 19.0 
17.5 
0,11 
0,89 0.6%, 20-30 cm 
DIIS427 cCIII-4® EcoRl 21; 16 9.0 - 9.6 4 alleles 0.5-0.6%, 30 cm 
D11S750 CCLGW4® Sad several 3.6 
2.4 
0.80 
0.20 
DIIS807 CCLGW39® Sad several s.4 
4..S 
0.70 
0.30 0,9%, 20 cm 
D11S449 cCIII-219® PvuII several 37 
3.0 
0,33 
0.67 
D11S97 pMS51 Hadll/TaqI 1.3-4.3 9 alleles l%.20cm 
DUS 146 pHBI59 
cCL59® 
TaqI 
EcoRV 24; 18; 74 
1.2 
0.8 
7.1) 
(-.4 
0.55 
0.45 
0,22 
0.78 0.9%, 20 cm 
DIIS75I cCL-8® EcoRV 20; 5.2; 2.2 6,6 
5,8 
0.50 
0,50 0.8%, 20 cm 
Sad 16; 12; 4; 3 10,0 
9.2 
0..50 
0.50 0.8%, 20 cm 
clone 8 EcoRl 7.4 
6.7 
0.89 
0.11 0.6%, 20-30 cm 
INT2 SS6 TaqI 
BamHI 
4.1 
2.3 
84 
5.6-1-2.8 
0.60 
0.40 
0.63 
0.37 
*Electrophoresis conditions are only indicated when special conditions are needed. 
Note: Loci in bold indicate "anchor markers" previously mapped on reference families. Loci in italics indicate those located closest to the MEN 1 gene. 
>) indicates probes with repetitive elements for which human DNA was included in the hybridization. 
tent. Haplotyping of the two markers for the PYGM locus and 
the combined D11S97 + DIIS 146 markers is also possible 
since these markers are closely linked. Details for isolation and 
restriction enzyme cleavage of DNA, Southem analysis, and hy-
bridization to radioactively-labeled probes have been described 
(10). 
Discussion 
Localization of the MEN 1 gene to chromosomal region 
llqll-ql3 
Localization of tumor predisposing genes has been facilitated 
in several conditions such as retinoblastoma and familial poly-
posis coli by identification of constitutional chromosomal aber-
rations. This has not been possible in MEN 1. Our working hy-
pothesis was that MEN 1-associated tumors may result from un-
masking of a recessive mutation according to the two-mutation 
model originally postulated by Knudson (11). Genetic rear-
rangements in such tumors would indicate on which chromo-
some MENl is situated. Such rearrangements would be ex-
pected in all tumor cells, restricted to a specific chromosome 
(12), and would serve to eliminate the wild type allele of MEN 1. 
We compared constitutional and tumor genotypes at different 
chromosomal loci in two brothers with insulinomas who had in-
herited the disease from their mother (5). Markers on 17 chro-
mosomes showed retained genotypes, but both tumors had lost 
one ofthe constitutional alleles at all informative loci on chro-
mosome 11. Combined pedigree and genotype analysis re-
vealed that the lost alleles were always derived from the unaf-
fected father (5). These findings fit the hypothesis that the tu-
mors resulted from elimination of the two MENl alleles (13). 
Subsequentiy, the tentative localization was confirmed by dem-
onstration of linkage between MEN 1 and the PYGM locus at 
1 lql3 in three families (5). No meiotic recombinations were ob-
served and the odds in favor of linkage were lO"*-^ :^ 1, which is 
well above the level of significance accepted for linkage analy-
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sis. The localization was later confirmed in four other families 
(14,15). 
The linkage map around the MENl locus (16,17) includes 7 
polymorphic "anchor markers" covering approximately 12 cM; 
l lp - (D11S149-D11S288) -PGA-PYGM- (Dl 1S97-D11S146-
INT2). These markers were analyzed in five families and mei-
otic crossovers were identified for markers at both ends of this 
region (16). 
Panel of polymorphic DNA markers 
We then attempted to develop a reliable and accurate DNA-
based diagnostic procedure for the MEN 1 predisposition (6). 
To be of clinical use such procedures should fulfill the following 
criteria: 
1. Meiotic crossing-over between the disease and the marker 
loci must be rare and should be detectable. This can be achieved 
by using markers close to, as well as flanking, the locus on both 
sides. 
2. Incorrect diagnosis of an individual, nonpaternity, or mix-
ing of samples are possible causes of incorrect results from 
DNA-based testing of inherited diseases. Nonpaternity or sam-
ple mixups can sometimes be recognized if several markers are 
used in the linkage analysis. 
DNA-based testing procedures can make use of the detailed 
genetic mapping data recently generated for the chromosomal 
region l lqll-13 (9,18,19). This involved isolation of new ge-
netic markers which have been mapped physically utilizing so-
matic cell hybrids or pulsed-field gel electrophoresis. Using dif-
ferent polymorphic DNA markers, we genotyped 124 members 
of six MEN 1 families, including 59 affected individuals, and 
determined the genetic linkage between MENl and these 
marker systems (6). Fourteen marker systems (18 DNA probes) 
were found to be linked to MENl. Four of the marker systems 
were on the centromeric side of MENl while the others were ei-
ther telomeric or close to MENl. The markers, their alleles, and 
experimental conditions are listed in the Table. The order from 
centromere (top) to telomere is based on combined data from 
linkage and physical mapping (9,16-19) and the markers closest 
to MENl are italicized (Table). 
DNA-based diagnosis of MEN 1 
DNA-based predictive testing for MEN 1 utilizes markers lo-
cated close to the disease gene on chromosome 11. In a kindred 
with at least two affected members it is possible to follow the 
disease gene by the segregation of the marker alleles thereby 
identifying the haplotype for this chromosomal region carrying 
the MENl mutation. In most clinical situations, it is possible to 
identify a haplotype with the mutant MEN 1 allele in the middle 
ifthe described set of markers is used (Figure). With two fiank-
ing marker systems informative, the calculated predicted accu-
racy would be greater than 99.5%. The practical considerations 
of such DNA-based testing are described in the following exam-
ples: 
1. A large family where several members can be genotyped: 
This is the "easiest" situation, where the family alone is large 
enough to show linkage between MEN 1 and the RFLP markers. 
PGA -pcAGPg 2 
PYGM-pMCMPr 1 
D11S97 4 4 ^ 
2 1 
3 3 
2 1 
2 1 
3 3 
2 1 
Figure—Pedigree illustrating DNA-based predictive testing for 
MEN 1. Filled .symbols indicate affected family members. Num-
bers below each individual indicate the genotypes for the infor-
mative marker systems listed next to the symbol of the carrier 
parent. The haplotypes for each individual are depicted along 
an illustrated chromosome segment with the inferred mutant 
chromosome indicated hy a thin line and the wild type chromo-
some of the carrier parent hatched. As illustrated, the two 
younger children have not shown any signs of MEN 1. The hap-
lotypes illustrate that the first daughter (II-l) and the brother 
(II-4, age 25) can-y the disease gene, while the second (11-2, age 
36) and third daughters (11-3, age 26) are not gene carriers. 
2. A family where only a few persons can be genotyped: 
There is a theoretical possibility of genetic heterogeneity be-
tween MEN 1 families which could be overlooked in this type of 
family. This issue will be clarified by genetic analysis of addi-
tional MEN 1 families although the disease gene has been linked 
to 1 lql3 in all 11 reported families (5,6,14-16). 
3. A family where only one affected individual can be ana-
lyzed: Generally, linkage analysis can only be applied when the 
haplotypes of at least two affected individuals can be compared. 
However, allele losses in MEN 1-associated pancreatic and 
parathyroid tumors serve to eliminate the wild type allele (5,20). 
Tumor studies could therefore be used to identify which hap-
lotype carries the mutated MEN 1 allele. However, pituitary and 
adrenocortical tumors could not be used for this purpose since 
the former are rarely operated on in MEN 1 patients and the lat-
ter have not shown allele losses for chromosome 11 markers 
(21). 
4. A single patient with MEN 1 syndrome: This patient most 
certainly has a constitutional predisposition to MEN 1. How-
ever, the mutational event may be prezygotic or postzygotic, 
and in the last situation it is not necessarily heritable. Hence, the 
offspring may all be without risk of developing MEN 1. 
5. A famdy with an "MEN 1-related" clinical picture: Again, 
the possibility of genetic heterogeneity must be taken into ac-
count. 
DNA-based diagnosis and biochemical screening provide a 
tool to detect individuals at risk of developing MEN 1 and to 
identify the neoplastic lesion at an early stage. A future goal will 
be to use these tools to decrease morbidity and mortality in 
MEN 1. 
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